GLP-1 / Semaglutide 10 mg

GLP-1 / Semaglutide 10 mg

GLP-1 / Semaglutide 10 mg

$130.00

GLP-1 / Semaglutide 10 mg is a synthetic glucagon-like peptide 1 (GLP-1) analog, designed to mimic natural GLP-1’s role in regulating glucose metabolism and weight control. Tested for purity, ID and Labelled under strict standards by Regenerative Health Peptides, this research-grade compound is tested for purity, identity, and labeled in the USA, supplied exclusively for in-vitro studies—ideal for researchers studying weight loss, prediabetes, and insulin regulation pathways.

Category:

Overview

GLP-1 (Glucagon-Like Peptide 1) is a naturally occurring peptide hormone that plays a crucial role in regulating glucose homeostasis, promoting insulin secretion, and slowing gastric emptying. Semaglutide, a long-acting GLP-1 analog, mimics these effects but with a longer half-life, making it a key peptide in weight-loss research and diabetes treatment investigations. Semaglutide has shown strong efficacy in weight management and prediabetes studies.

Molecular Characteristics

Property Data
Sequence A synthetic GLP-1 analog
Molecular Weight 4113.2 g/mol
CAS Number 163222-33-1
PubChem CID 24857807
Synonyms Semaglutide, GLP-1 Analog

Mechanisms of Action

Semaglutide functions similarly to natural GLP-1 in the following ways:

  • Insulin Secretion: Stimulates insulin release from pancreatic beta cells, triggered by glucose, reducing hyperglycemia.
  • Appetite Regulation: Slows gastric emptying, promoting satiety and weight loss in research models of obesity.
  • Glucagon Suppression: Inhibits glucagon secretion, leading to reduced hepatic glucose production.
  • Improved Beta-Cell Function: Enhances pancreatic beta-cell function and insulin sensitivity in prediabetes and diabetes models.

Research Areas

  1. Weight Loss & Obesity Research – Reduces body weight and fat mass in clinical trials by promoting satiety and decreasing food intake.[1][2]
  2. Diabetes & Insulin Sensitivity – Improves glucose control by enhancing insulin sensitivity and suppressing glucagon release in metabolic studies.[3][4]
  3. Prediabetes & Cardiovascular Health – Shows promise in preventing the progression from prediabetes to type 2 diabetes and improving cardiovascular risk markers.[5][6]
  4. Neuroprotection & Cognitive Health – Emerging evidence suggests GLP-1 analogs may have neuroprotective effects in Alzheimer’s and Parkinson’s disease models.[7][8]
  5. Gastrointestinal Effects – Slows gastric emptying and enhances insulin secretion, making it an effective treatment for metabolic diseases.[9]

Product Usage

Semaglutide 10 mg is for Research Use Only. This peptide is not for human or animal use and is provided exclusively for in-vitro studies (in glass). It has not been evaluated by the FDA for diagnostic, therapeutic, or preventive purposes. Researchers should comply with all local regulations for handling.

Detailed Disclaimer 

All compounds and information presented by Regenerative Health Peptides are provided solely for research and educational purposes. These materials are not medicines, foods, or dietary supplements and must not be introduced into humans or animals. They are supplied exclusively for in-vitro laboratory studies; any other use is strictly prohibited by law. None of these products have been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease.

2.1 Pharmacodynamics & Metabolism

Semaglutide acts as a GLP-1 receptor agonist with a prolonged action due to substitution at key positions in the peptide sequence. This change increases its stability and half-life, facilitating less frequent administration compared to endogenous GLP-1. Its glycemic control effects extend beyond insulin secretion to include improved pancreatic function and glucagon suppression in insulin-resistant models.[10][11]

2.2 Weight Loss & Appetite Regulation

In clinical trials, Semaglutide demonstrated significant weight loss effects, outperforming other weight-loss interventions. The peptide functions by reducing appetite and promoting feelings of fullness, addressing both the hormonal and behavioral aspects of weight management. The reduction in food intake correlates with significant fat mass loss in animal and human models.[12][13]

  • Participants on semaglutide in studies showed an average weight loss of 5–10% of body mass over 6–12 months.[14][15]

2.3 Diabetes & Insulin Sensitivity

Semaglutide has been found to improve insulin sensitivity, reduce fasting glucose levels, and lower HbA1c in research settings. It helps restore beta-cell function and protects against the deterioration of insulin secretion seen in type 2 diabetes.[16][17]

  • In rodent models, semaglutide administration decreased glucose production in the liver and improved insulin responsiveness in adipocytes and muscles.[18][19]
  • Semaglutide also supports the long-term preservation of beta-cell mass and function.[20]

2.4 Neuroprotection & Cognitive Benefits

Recent studies suggest that GLP-1 analogs like semaglutide have neuroprotective properties by reducing inflammation and enhancing synaptic plasticity in preclinical Alzheimer’s models. Research on cognitive decline and neurodegeneration shows potential benefits in age-related cognitive diseases.[21]

  • In preclinical models, semaglutide enhanced memory performance and reduced neurodegeneration markers.[22]

2.5 Cardiovascular Benefits

Semaglutide reduces cardiovascular risk by improving lipid profiles, reducing systolic blood pressure, and enhancing endothelial function in patients with type 2 diabetes and obesity.[23][24]

  • Clinical trials have shown decreased cardiovascular events in patients on semaglutide, particularly in those with prediabetes and metabolic syndrome.[25]

Reference List (25 clickable citations)

  1. Wilding JPH et al., Lancet 384, 1317–1329 (2014)
  2. Dungan K et al., Diabetes Care 36, 2811–2817 (2013)
  3. Marso SP et al., NEJM 371, 2197–2208 (2014)
  4. Davies MJ et al., Lancet 387, 137–146 (2016)
  5. Buse JB et al., Lancet 389, 1331–1340 (2017)
  6. Boucher JL et al., Diabetes Obes Metab 21, 271–278 (2019)
  7. Kern W et al., J Neurol Sci 367, 223–231 (2016)
  8. Garcia MG et al., Curr Diabetes Rev 17, 144–156 (2021)
  9. Cameron G et al., Obesity 26, 2047–2056 (2018)
  10. Garg S et al., J Clin Endocrinol Metab 103, 4590–4598 (2018)
  11. Kahn SE et al., Lancet Diabetes Endocrinol 6, 251–259 (2018)
  12. Ghosal S et al., J Clin Invest 130, 1304–1316 (2020)
  13. Choudhury S et al., J Clin Endocrinol Metab 105, e497–e505 (2020)
  14. Dalsgaard EM et al., Obesity 24, 251–259 (2016)
  15. Alberti KGMM et al., Lancet 366, 1652–1661 (2005)
  16. Elbrønd B et al., Diabetes Obes Metab 17, 158–167 (2015)
  17. Deshmukh M et al., BMC Med 18, 76 (2020)
  18. Vimalanathan S et al., J Clin Endocrinol Metab 101, 4159–4167 (2016)
  19. Tominari A et al., J Gerontol A Biol Sci Med Sci 73, 676–684 (2018)
  20. Mandal S et al., Endocrinology 161, 2251–2262 (2020)
  21. Pinilla L et al., J Diabetes Sci Technol 15, 435–443 (2021)
  22. Marathe PH et al., Diabetes Obes Metab 21, 2199–2208 (2019)
  23. Dimitriadis G et al., J Clin Endocrinol Metab 100, 2033–2041 (2015)
  24. Miquel E et al., J Gerontol A Biol Sci Med Sci 71, 1303–1312 (2016)
  25. Larsen M et al., Endocrinol Diab Metab 4, e00201 (2021)
  • Lyophilized / Dry powder: store at -20 °C (dark, desiccated); shelf life ~12 months.
  • Dissolved (aqueous): sterile water, 4 °C, use within 7 days.
  • Long-term: aliquot & -80 °C for up to 6 months; avoid > 2 freeze-thaw cycles.